RIVAROXABAN

Brand name:

• Xarelto®

Pharmaceutical company:

Bayer Australia Ltd

Condition/indication:
(therapeutic use)

• Coronary Artery Disease (CAD) and Peripheral Artery Disease (PAD)

PBAC Submission type:

New listing (Major)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – March 2020

Related medicines:

--

Submission received for:

March 2020 PBAC meeting

Opportunity for consumer comment:

Open 24/12/2019 and close 12/02/2020 (see PBS Website)

PBAC meeting:

Held on 11/03/2020

PBAC outcome published:

Deferred (see PBAC Outcomes)

Lodgement of required documentation:

Not applicable

Agreement to listing arrangements:

Not applicable

Government processes:

Not applicable

Medicine listed on the PBS:

Not applicable

---